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The Endocannabinoid System (ECS) comprising the CB1 and CB2 receptors and 
their endogenous ligands is a central signalling system regulating food intake and 
energy balance. It is also present in peripheral tissues where it is involved in cell pro-
liferation and survival. It has been shown that in colon cancer cells, the CB1 receptor 
antagonist SR171416 reduces colon cancer cell growth by acting as an inverse agonist 
rather than an antagonist [1]. Starting from this observation and from evidence indi-
cating that some biological responses to cannabinoids depend on estrogen levels and 
some selective estrogen receptor modulators can bind the CB1 receptor [2], we aimed 
to study the effects of the CB1 receptor ligand anandamide (AEA) on colon cancer 
cell proliferation and its ability to modulate some survival and proliferating path-
ways including Akt, MAPK/ERK and estrogen receptor (ER) b signalling which is 
the predominant ER pathway in colonic epithelium. We used an AEA-analogue and 
a selective inhibitor of fatty acid amide hydrolase (FAAH) that enhances intracellular 
levels of AEA and studied proliferation and cell cycle progression on human adeno-
carcinoma cells DLD1 and SW620. Our results showed that increased levels of AEA 
significantly reduced cell proliferation in both cell lines at 24 and 48 h also inducing 
an S phase cell cycle accumulation. The AEA-induced inhibition of cell growth was 
mediated by a reduced expression of phoshoAkt and phosphoERK and, at the same 
time, by an induction of ERβ expression. These data suggest that AEA can reduces 
colon cancer cell proliferation by interfering with different signalling pathways.
References
[1] Santoro A et al. (2009) Rimonabant inhibits human colon cancer cell growth and reduces the for-
mation of precancerous lesions in the mouse colon. Int J Cancer 125:996-1003.
[2] Franks LN et al. (2016) Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse 
Agonists with Differential CB1 and CB2 Selectivity. Front Pharmacol 7:503-519.
Keywords
Endocannabinoid system, anandamide, colon cancer cells, Akt and MAPK/ERK pathways, oes-
trogen receptor β signaling
